MIRM Stock Overview
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Mirum Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$31.70 |
| 52 Week High | US$33.39 |
| 52 Week Low | US$17.49 |
| Beta | 1.2 |
| 1 Month Change | 5.67% |
| 3 Month Change | 14.77% |
| 1 Year Change | 72.94% |
| 3 Year Change | 33.47% |
| 5 Year Change | n/a |
| Change since IPO | 139.97% |
Recent News & Updates
Recent updates
What Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) P/S Is Not Telling You
Jun 10
Industry Analysts Just Made A Captivating Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Revenue Forecasts
Apr 18Mirum's liver disease drug Livmarli gets EMA committee nod for approval in EU
Oct 14Mirum: Great Sales Start For Livmarli Paves The Way For Long-Term Growth
Aug 17Mirum Pharmaceuticals announces $80M stock offering
Aug 09Mirum Pharmaceuticals: Post-Approval Execution Looks Excellent
May 27Is Mirum Pharmaceuticals (NASDAQ:MIRM) In A Good Position To Invest In Growth?
Apr 22Mirum Pharmaceuticals Gets The 'Thumbs Up'
Dec 16Need To Know: Analysts Just Made A Substantial Cut To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates
Nov 25Mirum And Maralixibat In Pediatric Cholestasis: The Differentiation
Aug 24Analysts Have Made A Financial Statement On Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Second-Quarter Report
Aug 09We're Keeping An Eye On Mirum Pharmaceuticals' (NASDAQ:MIRM) Cash Burn Rate
Jul 28Mirum Is Undervalued Despite Expected Tough Competition
Jun 01Mirum gets notice of allowance from United States Patent and Trademark Office
Apr 26We're Not Very Worried About Mirum Pharmaceuticals' (NASDAQ:MIRM) Cash Burn Rate
Mar 29What Type Of Shareholders Make Up Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Share Registry?
Feb 22Mirum kicks off enrolment in Phase 2b VISTAS study of volixibat
Jan 14Mirium Pharmaceuticals +4%, provides corporate update
Jan 12Christopher Peetz Is The President of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) And They Just Picked Up 2.5% More Shares
Dec 30Shareholder Returns
| MIRM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.1% | 3.8% | 0.9% |
| 1Y | 72.9% | -5.8% | 13.6% |
Return vs Industry: MIRM exceeded the US Biotechs industry which returned -7.8% over the past year.
Return vs Market: MIRM exceeded the US Market which returned 11.7% over the past year.
Price Volatility
| MIRM volatility | |
|---|---|
| MIRM Average Weekly Movement | 6.7% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: MIRM is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: MIRM's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 249 | Chris Peetz | https://www.mirumpharma.com |
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company’s lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults.
Mirum Pharmaceuticals, Inc. Fundamentals Summary
| MIRM fundamental statistics | |
|---|---|
| Market Cap | US$1.49b |
| Earnings (TTM) | -US$164.19m |
| Revenue (TTM) | US$144.73m |
10.2x
P/S Ratio-9.0x
P/E RatioIs MIRM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MIRM income statement (TTM) | |
|---|---|
| Revenue | US$144.73m |
| Cost of Revenue | US$26.51m |
| Gross Profit | US$118.21m |
| Other Expenses | US$282.40m |
| Earnings | -US$164.19m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.52 |
| Gross Margin | 81.68% |
| Net Profit Margin | -113.45% |
| Debt/Equity Ratio | 113.7% |
How did MIRM perform over the long term?
See historical performance and comparison